RhumbLine Advisers
ACTU

RhumbLine Advisers’s Actuate Therapeutics ACTU Stock Holding History

RhumbLine Advisers’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.54K Sell
3,620
-5,734
-61% -$13.3K ﹤0.01% 3957
2026
Q1 		$25.6K Sell
9,354
-180
-2% -$746 ﹤0.01% 3692
2025
Q4 		$58.3K Buy
9,534
+766
+9% +$5.26K ﹤0.01% 3609
2025
Q3 		$58.7K Sell
8,768
-314
-3% -$2.28K ﹤0.01% 3635
2025
Q2 		$55.5K Buy
+9,082
New +$79.3K ﹤0.01% 3655

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

RhumbLine Advisers's ACTU Position: Q2 2026 in Review

RhumbLine Advisers reduced its Actuate Therapeutics (ACTU) stake by 61% in Q2 2026, selling an estimated $13.3K and leaving 3,620 shares worth $5.54K. The position accounts for ﹤0.01% of the portfolio, ranked #3957.

RhumbLine Advisers first reported a position in ACTU in Q2 2025 and has held it in 5 quarters since. The position peaked at $58.7K in Q3 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • RhumbLine Advisers held 3,620 shares of Actuate Therapeutics worth $5.54K as of Q2 2026.
  • RhumbLine Advisers sold 5,734 Actuate Therapeutics shares in Q2 2026, an estimated $13.3K.
  • Actuate Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3957 holding.
  • RhumbLine Advisers first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • RhumbLine Advisers's Actuate Therapeutics position peaked at $58.7K in Q3 2025.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.